CN1489462A - Blood lipid ameliopant composition - Google Patents
Blood lipid ameliopant composition Download PDFInfo
- Publication number
- CN1489462A CN1489462A CNA018226396A CN01822639A CN1489462A CN 1489462 A CN1489462 A CN 1489462A CN A018226396 A CNA018226396 A CN A018226396A CN 01822639 A CN01822639 A CN 01822639A CN 1489462 A CN1489462 A CN 1489462A
- Authority
- CN
- China
- Prior art keywords
- tocopherol
- alpha
- simvastatin
- riboflavin
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
A blood lipid ameliorating composition containing simvastatin and one or more ingredients selected from a riboflavin compound, a d-alpha-tocopherol compound, an ascorbic acid compound, pantethine, and taurine.
Description
Technical field
The present invention relates to lipid ameliopant composition in a kind of blood, its contain simvastatin and be selected from riboflavin class, tocopherols, ascorbic acid class, pantethine and the taurine more than a kind or 2 kinds.
Background technology
When lipid peroxide increases at blood middle concentration, have and cause effects such as arteriosclerotic vascular endothelial cell obstacle, platelet aggregation are hyperfunction, foam cell formation, so lipid peroxide-lowering is useful medicine.
Simvastatin is to pass through in vivo to suppress the HMG-CoA reductase, has the medicine that reduces the effect of T-CHOL amount in the blood, the effect of lipid peroxide in the also known reduction blood.
On the other hand; the antioxidation of riboflavin class, tocopherols and ascorbic acid class is well-known; in addition for pantethine and taurine; also known effect (document: sulfur-containing amino acid with lipid peroxide in the reduction blood; Vol.7 No.1 1984 p.201-205 and Geriat.Med., Vol.19 No.3 1981 is p.415-422).
Disclosure of the Invention
The inventor constantly concentrate one's attention on to study to the compositions that reduces lipid peroxidation quality in the blood, found that by with simvastatin and certain vitamins or taurine coupling, can significantly reduce in the blood lipid peroxidation quality etc., thereby finish the present invention.
The present invention is a lipid ameliopant composition in a kind of blood, its contain simvastatin and be selected from riboflavin class, tocopherols, ascorbic acid class, pantethine and the taurine more than a kind or 2 kinds.
Simvastatin be meant (+)-(1S, 3R, 7S, 8S, 8aR)-1,2,3,7,8,8 a-six hydrogen-3,7-dimethyl-8-[2-[(2R, 4R)-and tetrahydrochysene-4-hydroxyl-6-oxo-2H-pyrans-2-yl] ethyl]-1-naphthyl 2,2-dimethyl butyrate acid esters and salt thereof (particularly sodium salt) and acid thereof.
The riboflavin class is meant the acid esters of riboflavin such as riboflavin and Riboflavin butyrate, preferred riboflavin, Riboflavin Sodium Phosphate, Riboflavin butyrate, flavin adenine dinucleotide (FAD) or Flavin Adenin Dinucleotide Sodium, more preferably Riboflavin Sodium Phosphate or Riboflavin butyrate, preferred especially Riboflavin butyrate.
Tocopherols is meant the acid esters of tocopherol (raceme and optically active body) and tocopheryl acetate tocopherols such as (raceme and optically active bodies), preferred succinic acid d-alpha-tocopherol, succinic acid d1-alpha-tocopherol, succinic acid d1-alpha-tocopherol calcium, acetic acid d-alpha-tocopherol, acetic acid d1-alpha-tocopherol, d-alpha-tocopherol or d1-alpha-tocopherol, more preferably succinic acid d1-alpha-tocopherol or acetic acid d-alpha-tocopherol, preferred especially acetic acid d-alpha-tocopherol.
The ascorbic acid class is meant the acid esters of ascorbic acid such as Ascorbate such as ascorbic acid, sodium ascorbate and ascorbyl stearate, preferred ascorbic acid, sodium ascorbate or calcium ascorbate, more preferably ascorbic acid.
Pantethine is meant 2,4-dihydroxy-N-[3-[(2-mercaptoethyl) amino]-the 3-oxopropyl]-3, the 3-amide dimethyl butyrate.
Taurine is meant 2-aminoethyl sulfonic acid and salt thereof.
Lipid peroxide is the lipid peroxide that is present in the blood in the blood, comprises for example peroxidating LDL (low density lipoprotein, LDL) etc.
" improvement " of lipid ameliopant is meant that clinically improve the free burial ground for the destitute intentionally in the blood.
Lipid ameliopant composition is in the occasion of solid preparation in the blood of the present invention; the weight % of the simvastatin that contains is generally 0.005～3%; preferred 0.03～2%; the weight % of riboflavin class is generally 0.002～40.0%; preferred 0.01～20.0%; the weight % of ascorbic acid class is generally 0.05～50.0%; preferred 0.5～25.0%, and the weight % of tocopherols is generally 0.002～40.0%; preferred 0.02～20.0%; in addition, the weight % of pantethine is generally 0.3～50%, and preferred 1.0～20%; and the weight % of taurine is generally 0.3～50%, preferred 1～25%.
Lipid ameliopant composition is in the occasion of liquid preparation in the blood of the present invention; the content of the simvastatin that contains is generally 0.03～1mg/mL; preferred 0.05～0.5mg/mL; in addition; the content of riboflavin class is generally 0.05～5mg/mL; preferred 0.1～3mg/mL; the content of ascorbic acid class is generally 1～20mg/mL, preferred 2～10mg/mL, and also the content of tocopherols is generally 0.5～5mg/mL; preferred 1.5～3mg/mL; in addition, the content of pantethine is generally 0.5～20mg/mL, preferred 1～10mg/mL; and the content of taurine is generally 1.0～50mg/mL, preferred 2～35mg/mL.
Concrete dosage form as lipid ameliopant composition in the blood of the present invention, for example tablet, granula subtilis (comprising powder), capsule, liquid preparation etc., can suitably use the additive or the substrate that are suitable for various dosage forms, be prepared according to the conventional method of records such as Japanese Pharmacopoeia.
In the above-mentioned various dosage form,, also can use normally used various additive according to its dosage form.
For example, the occasion of tablet can use lactose, crystalline cellulose etc. as excipient, and use metasilicic acid magnesium aluminate etc. are as stabilizing agent, and use hydroxypropyl cellulose etc. are as binding agent, and use magnesium stearate etc. are as lubricant.
The occasion of granula subtilis and capsule can use lactose, refined sucrose etc. as excipient, and use metasilicic acid magnesium aluminate etc. are as stabilizing agent, and use corn starch etc. use hydroxypropyl cellulose, polysorbate etc. as binding agent as adsorbent.
The occasion of liquid preparation, can use D-sorbitol solution, Mel etc. as sweeting agent, use d1-malic acid etc. are as correctives, and use sodium ethylene diamine tetracetate etc. are as stabilizing agent, use ethanol etc. use stearic acid polyoxyethylene hardened castor oil 60 grades as solubilizing agent as dissolution aids.
In the above-mentioned various dosage form, as required, also can add disintegrating agents such as polyvinylpolypyrrolidone, adsorbents such as calcium silicates, coloring agent such as iron sesquioxide, caramel, pH regulator agent such as sodium benzoate, spice.
When giving compositions of the present invention, can give the various compositions of compositions simultaneously, perhaps certain hour gives the various compositions of compositions respectively at interval.
Above-mentioned " simultaneously " administration, so long as can get final product at the administering mode of much at one time administration, there is no particular limitation, preferably as single compositions administration.
In addition, above-mentioned " certain hour is respectively at interval " administration, so long as can get final product at the administering mode of different time difference administrations, there is no particular limitation, for example gives a kind of composition, then after the time that process is determined, gives the method for other composition.
In addition, when the one-tenth subtotaling of the compositions that gives has more than 3 kinds, " while or interval certain hour are respectively " gives, comprise the method that gives all these compositions simultaneously, difference interval certain hour is the method for independent administration separately, gives simultaneously more than 2 kinds, and certain hour gives the method for residual drug at interval, perhaps certain hour gives more than 2 kinds at interval, gives the method for residual drug etc. then simultaneously.
The preferred forms of invention
Below exemplify embodiment etc., further describe the present invention, but the present invention is not subjected to the qualification of these embodiment.
Embodiment 1 tablet
(1) composition
Table 1
＜riboflavin〉＜ascorbic acid〉＜tocopherol〉＜pantethine〉＜taurine 〉
In 4 in 4 in 4 in 4 in 4
(800mg) (1200mg) (900mg) (1200mg) (1200mg)
Simvastatin 10mg 10mg 10mg 10mg 10mg
Riboflavin butyrate 100mg----
Ascorbic acid-500mg---
Succinic acid dl---200mg--
Alpha-tocopherol
Pantethine---500mg-
Taurine----500mg
(taurine)
Crystalline cellulose 120mg 12mg 12mg 12mg 120mg
Metasilicic acid magnesium aluminate 144mg---144mg
Sucrose fatty acid ester-140mg 108mg 140mg-
Hydroxypropyl cellulose 96mg 48mg 48mg 48mg 96mg
Magnesium stearate 24mg 24mg 24mg 24mg 24mg
Polyvinylpolypyrrolidone 100mg 48mg 48mg 48mg 100mg
Lactose is an amount of an amount of
(2) method for making
By the amount of above-mentioned each composition, measure mentioned component, according to a preparation of Japanese Pharmacopoeia preparation general provisions " tablet " tablet.
Embodiment 2 granula subtilises
(1) composition
Table 2
＜riboflavin〉＜ascorbic acid〉＜tocopherol〉＜pantethine〉＜taurine 〉
4 the bag in 4 the bag in 4 the bag in 4 the bag in 4 the bag in
(4g) (5.2g) (4.2g) (4.6g) (5.2g)
Simvastatin 10mg 10mg 10mg 10mg 10mg
Riboflavin butyrate 100mg----
Ascorbic acid-1.0g---
Succinic acid d1---200mg--
Alpha-tocopherol
Pantethine---500mg-
Taurine----1.0g
(taurine)
Refined sucrose 1.4g 1.6g 1.4g 1.6g 1.4g
Steelvia chrysanthemum-16mg-16mg-
(stevia) extract
Corn starch 1.2g 1.2g 1.2g 1.2g 1.2g
Polysorbate80 80mg 48mg 48mg 48mg 80mg
Metasilicic acid magnesium aluminate 144mg-128mg-144mg
Magnesium stearate 24mg 24mg 24mg 24mg 24mg
Lactose is an amount of an amount of
(2) method for making
By the amount of above-mentioned each composition, measure mentioned component, according to a preparation of Japanese Pharmacopoeia preparation general provisions " granule " granule.
Embodiment 3 capsules
(1) composition
Table 3
＜riboflavin〉＜ascorbic acid〉＜tocopherol〉＜pantethine〉＜taurine 〉
In 4 capsules in 8 capsules in 4 capsules in 8 capsules in 8 capsules
Simvastatin 10mg 10mg 10mg 10mg 10mg
Riboflavin butyrate 100mg----
Ascorbic acid-500mg---
Succinic acid d1---200mg--
Alpha-tocopherol
Pantethine---500mg-
Taurine----500mg
(taurine)
Corn starch 960mg 960mg 840mg 960mg 960mg
Polysorbate80 80mg 48mg 48mg 48mg 80mg
Metasilicic acid magnesium aluminate 144mg-128mg-144mg
Magnesium stearate 24mg 24mg 24mg 24mg 24mg
Lactose is an amount of an amount of
Subtotal 1520mg 1940mg 1580mg 1940mg 2008mg
Capsule 320mg 640mg 320mg 640mg 640mg
Add up to 1840mg 2580mg 1900mg 2580mg 2648mg
(2) method for making
By the amount of above-mentioned each composition, measure mentioned component, according to a preparation of Japanese Pharmacopoeia preparation general provisions " granule " granula subtilis, be filled to then in the capsule, make hard capsule.
Embodiment 4 liquid preparations
(1) composition
Table 4
＜riboflavin〉＜ascorbic acid〉＜tocopherol〉＜pantethine〉＜taurine 〉
Among the 100mL among the 100mL among the 100mL among the 100mL among the 100mL
Simvastatin 10mg 10mg 10mg 10mg 10mg
Riboflavin Sodium Phosphate 200mg----
Ascorbic acid-500mg---
Acetic acid d-
Alpha-tocopherol--50mg--
Pantethine---500mg-
Taurine----500mg
(taurine)
D-sorbitol liquid 4g 6g 4g 6g 4g
(70％)
Mel 7g 8g 7g 8g 7g
D1-malic acid 200mg-200mg-200mg
Sodium ethylene diamine tetracetate 20mg 20mg 20mg 20mg 20mg
Ethanol 2mL 2mL 2mL 2mL 2mL
Stearic acid polyoxyethylene 100mg 100mg 100mg 100mg 100mg
Hardened castor oil 60
Sodium benzoate 60mg 60mg 60mg 60mg 60mg
Spice trace trace trace trace trace
Distilled water is an amount of an amount of
(2) method for making
By the amount of above-mentioned each composition, measure mentioned component, according to a preparation of Japanese Pharmacopoeia preparation general provisions " liquid preparation " liquid preparation.
The evaluation test of the improvement effect of lipid peroxidation quality etc. in (test example) blood
＜test method 〉
(1) measured matter
The product of Chemtech Labo, the pharmacy of SANLING Tokyo, Eisai, Japanese ROCHE, Nacalai Tesque, the first pharmacy system is purchased and used to simvastatin, Riboflavin butyrate, acetic acid d-alpha-tocopherol, ascorbic acid, pantethine and taurine respectively.
(2) experimental animal
As experimental animal,, raise the back use through about 1 month quarantine and domestication by the male beagle (Beagle) that Covance Research Products Inc. bought for 5 monthly ages.
(3) store method of form of administration, preparing preparation and preparation
In the gelatine capsule of buying by TORPAC company (1/2 ounce), fill the simvastatin or the various compounding ingredient of the necessary amount of calculating according to each experimental animal weighing machine.In addition, the capsule after simvastatin is filled is preserved before administration under cold preservation, and the capsule of loading of stock is at room temperature preserved before administration.
In addition, the occasion of compounding ingredient is filled in the identical gelatine capsule.
(4) during route of administration and the administration
9:00～12:30 between forced oral give and experimental animal 1 the capsule every day that is filled with simvastatin or compounding ingredient.In addition, experimental animal before administration 2 to 3 hours jejunitas.
Be 11 days during the administration.
(5) preparation of tested sample and test method
Begin to capsule before the 1st week and the 2nd week, administration 4 days, 8 days and 12 days get the about 10mL of blood by cephalic vein.In addition, get the blood precontract 18 hours, give experimental animal jejunitas.With the blood collecting that obtains in test tube, place after 30 minutes to 1 hour under the room temperature, centrifugalize (3000rpm, 10 minutes), the serum that use obtains adopts Yagi spark gap method, CEH-COD-POD method, GK-GPO-POD method, ACS-ACOD-POD method, UV-rate method and UV-rate method to measure lipid peroxide, T-CHOL, triglyceride, free fatty, GOT and CPK content in the blood respectively.
In addition, in lipid peroxide and other Determination on content, use fluorophotometer F3000, the automatical analysis device Monarch of Instrumentation Laboratory society of Hitachi and the automatic analysing apparatus 7170 of Hitachi.
＜result of the test 〉
Meansigma methods with lipid peroxidation quality in the blood before administration 2 week and 1 week etc. is 100, lipid peroxidation quality etc. in the blood of the convert single agent of obtaining simvastatin and Riboflavin butyrate, acetic acid d-alpha-tocopherol, ascorbic acid, pantethine and taurine dosage separately and compounding ingredient.Each numerical value is 1 group 5 meansigma methods.
(the coupling effect of simvastatin and Riboflavin butyrate)
Table 5
Lipid peroxidation quality in the measured matter blood
(mg/Kg) after the administration after the administration in 4 days after the administration in 8 days 12 days
Simvastatin list agent 96.2 86.4 91.0
(1mg)
Riboflavin butyrate list agent 88.9 101.0 80.8
(200mg)
Simvastatin 89.5 75.9 84.8
(1mg)
+ Riboflavin butyrate
(200mg)
Table 6
Free fatty acid amount in the measured matter blood
(mg/Kg) after the administration after the administration in 4 days after the administration in 8 days 12 days
Simvastatin list agent 93.8 99.3 97.0
(1mg)
Riboflavin butyrate list agent 97.6 101.2 92.9
(200mg)
Simvastatin 102.6 84.3 72.4
(1mg)
+ Riboflavin butyrate
(200mg)
(the coupling effect of simvastatin and acetic acid d-alpha-tocopherol)
Table 7
Lipid peroxidation quality in the measured matter blood
(mg/Kg) after the administration after the administration in 4 days after the administration in 8 days 12 days
Simvastatin list agent 96.2 86.4 91.0
(1mg)
Acetic acid d-alpha-tocopherol 106.3 119.0 75.9
Single agent
(300mg)
Simvastatin 85.1 67.2 75.2
(1mg)
+ acetic acid d-α-
Tocopherol
(300mg)
Table 8
Free fatty acid amount in the measured matter blood
(mg/Kg) after the administration after the administration in 4 days after the administration in 8 days 12 days
Simvastatin list agent 93.8 99.3 97.0
(1mg)
Acetic acid d-alpha-tocopherol 115.4 103.1 86.2
Single agent
(300mg)
Simvastatin 94.3 95.7 81.6
(1mg)
+ acetic acid d-α-
Tocopherol
(300mg)
Table 9
Measured matter GOT amount
(mg/Kg) after the administration after the administration in 4 days after the administration in 8 days 12 days
Simvastatin list agent 98.1 93.9 100.4
(1mg)
Acetic acid d-alpha-tocopherol 114.9 139.7 109.1
Single agent
(300mg)
Simvastatin 89.1 85.6 89.1
(1mg)
+ acetic acid d-α-
Tocopherol
(300mg)
(the coupling effect of simvastatin and ascorbic acid)
Table 10
Lipid peroxidation quality in the measured matter blood
(mg/Kg) after the administration after the administration in 4 days after the administration in 8 days 12 days
Simvastatin list agent 96.2 86.4 91.0
(1mg)
Ascorbic acid list agent 87.6 89.9 94.4
(500mg)
Simvastatin 85.3 75.7 78.9
(1mg)
+ ascorbic acid
(500mg)
Table 11
Free fatty acid amount in the measured matter blood
(mg/Kg) after the administration after the administration in 4 days after the administration in 8 days 12 days
Simvastatin list agent 93.8 99.3 97.0
(1mg)
Ascorbic acid list agent 87.4 109.6 97.8
(500mg)
Simvastatin 82.8 76.1 69.5
(1mg)
+ ascorbic acid
(500mg)
Table 12
Measured matter CPK amount
(mg/Kg) after the administration after the administration in 4 days after the administration in 8 days 12 days
Simvastatin list agent 94.5 99.4 91.0
(1mg)
Ascorbic acid list agent 98.3 95.1 91.5
(500mg)
Simvastatin 90.6 88.8 89.3
(1mg)
+ ascorbic acid
(500mg)
(the coupling effect of simvastatin and pantethine)
Table 13
Lipid peroxidation quality in the measured matter blood
(mg/Kg) after the administration after the administration in 4 days after the administration in 8 days 12 days
Simvastatin list agent 96.2 86.4 91.0
(1mg)
Pantethine 82.5 105.0 87.5
(300mg)
Simvastatin 83.8 75.4 75.9
(1mg)
+ pantethine
(300mg)
Table 14
Triglyceride mass in the measured matter blood
(mg/Kg) after the administration after the administration in 4 days after the administration in 8 days 12 days
Simvastatin list agent 97.6 88.9 89.3
(1mg)
Pantethine 104.4 103.9 96.6
(300mg)
Simvastatin 98.9 84.8 83.9
(1mg)
+ pantethine
(300mg)
(the coupling effect of simvastatin and taurine)
Table 15
Lipid peroxidation quality in the measured matter blood
(mg/Kg) after the administration after the administration in 4 days after the administration in 8 days 12 days
Simvastatin list agent 96.2 86.4 91.0
(1mg)
Taurine 95.8 93.8 87.5
(1000mg)
Simvastatin 83.7 76.2 80.5
(1mg)
+ taurine
(1000mg)
Table 16
T-CHOL amount in the measured matter blood
(mg/Kg) after the administration after the administration in 4 days after the administration in 8 days 12 days
Simvastatin list agent 102.1 93.2 86.6
(1mg)
Taurine 95.9 90.2 87.2
(1000mg)
Simvastatin 98.6 79.0 74.8
(1mg)
+ taurine
(1000mg)
Table 17
Triglyceride mass in the measured matter blood
(mg/Kg) after the administration after the administration in 4 days after the administration in 8 days 12 days
Simvastatin list agent 97.6 88.9 89.3
(1mg)
Taurine 98.6 95.8 80.8
(1000mg)
Simvastatin 97.2 77.1 71.4
(1mg)
+ taurine
(1000mg)
Industrial applicibility
The composition that Simvastatin of the present invention and ascorbic acid are formed by combining has good falling The effect of lipid peroxidation quality etc. is therefore useful as lipid ameliopant in the blood in the low blood.
Claims (14)
1. lipid ameliopant composition in the blood, its contain simvastatin and be selected from riboflavin class, tocopherols, ascorbic acid class, pantethine and the taurine more than a kind or 2 kinds.
2. compositions as claimed in claim 1, riboflavin class are riboflavin, Riboflavin Sodium Phosphate, Riboflavin butyrate, flavin adenine dinucleotide (FAD) or Flavin Adenin Dinucleotide Sodium.
3. compositions as claimed in claim 1, riboflavin class are Riboflavin Sodium Phosphate or Riboflavin butyrate.
4. compositions as claimed in claim 1, the riboflavin class is a Riboflavin butyrate.
5. as any described compositions in the claim 1 to 4, tocopherols is succinic acid d-alpha-tocopherol, succinic acid d1-alpha-tocopherol, succinic acid d1-alpha-tocopherol calcium, acetic acid d-alpha-tocopherol, acetic acid d1-alpha-tocopherol, d-alpha-tocopherol or d1-alpha-tocopherol.
6. as any described compositions in the claim 1 to 4, tocopherols is succinic acid d1-alpha-tocopherol or acetic acid d-alpha-tocopherol.
7. as any described compositions in the claim 1 to 4, tocopherols is an acetic acid d-alpha-tocopherol.
8. as any described compositions in the claim 1 to 7, the ascorbic acid class is ascorbic acid, sodium ascorbate or calcium ascorbate.
9. as any described compositions in the claim 1 to 7, the ascorbic acid class is an ascorbic acid.
10. lipid ameliopant composition in the blood contains simvastatin and Riboflavin butyrate.
11. lipid ameliopant composition in the blood contains simvastatin and ascorbic acid.
12. lipid ameliopant composition in the blood contains simvastatin and acetic acid d-alpha-tocopherol.
13. lipid ameliopant composition in the blood contains simvastatin and pantethine.
14. lipid ameliopant composition in the blood contains simvastatin and taurine.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP379879/2000 | 2000-12-14 | ||
| JP2000379879 | 2000-12-14 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1489462A true CN1489462A (en) | 2004-04-14 |
| CN100369605C CN100369605C (en) | 2008-02-20 |
Family
ID=18848165
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB018226396A Expired - Fee Related CN100369605C (en) | 2000-12-14 | 2001-12-12 | Blood lipid ameliopant composition |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7012067B2 (en) |
| CN (1) | CN100369605C (en) |
| AU (1) | AU2002221131A1 (en) |
| CA (1) | CA2433285C (en) |
| HK (1) | HK1061518A1 (en) |
| TW (1) | TWI277417B (en) |
| WO (1) | WO2002047682A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1329031C (en) * | 2005-01-24 | 2007-08-01 | 杭州鑫富药业有限公司 | Blood-fat regulating medicinal composition and use thereof |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI284529B (en) * | 2000-12-18 | 2007-08-01 | Sankyo Co | A composition for lowering triglyceride |
| JP2006509722A (en) * | 2002-07-03 | 2006-03-23 | エスペリオン セラピューティクス，インコーポレイテッド | Pantethine-containing composition for treating dyslipidemia |
| US20050187204A1 (en) * | 2002-08-08 | 2005-08-25 | Sankyo Company, Limited | Medicinal composition for lowering blood lipid level |
| US20050192347A1 (en) * | 2003-12-23 | 2005-09-01 | Dasseux Jean-Louis H. | Urea and thiourea compounds and compositions for cholesterol management and related uses |
| JP5080011B2 (en) * | 2005-02-28 | 2012-11-21 | 第一三共ヘルスケア株式会社 | Composition for increasing glutathione peroxidase activity |
| WO2007125339A1 (en) | 2006-04-26 | 2007-11-08 | Rosemont Pharmaceuticals Ltd | Liquid oral compositions |
| US20090076134A1 (en) * | 2007-09-17 | 2009-03-19 | Protia, Llc | Deuterium-enriched simvastatin |
| EP2220208A4 (en) * | 2007-11-23 | 2010-12-29 | Rappaport Family Inst For Res | Use of haptoglobin genotyping in diagnosis and treatment of cardiovascular disease |
| WO2013100080A1 (en) | 2011-12-27 | 2013-07-04 | 国立大学法人大阪大学 | Method for inducing differentiation enabling tumorigenesis of ips cells to be suppressed |
| BR112022001422A2 (en) | 2019-07-29 | 2022-03-22 | Matthias Rath | Ascorbate in the prevention of statin-induced vascular calcification |
| US11547693B2 (en) | 2019-07-29 | 2023-01-10 | Matthias Rath | Ascorbate in the prevention of statin induced vascular calcification |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6019891B2 (en) * | 1978-12-01 | 1985-05-18 | 第一製薬株式会社 | Drug-induced fatty liver agent |
| JPS5869813A (en) * | 1981-10-23 | 1983-04-26 | Sogo Yatsukou Kk | Serum lipid depressant |
| JPS6041611A (en) * | 1983-08-17 | 1985-03-05 | Sankyo Co Ltd | Blood lipid improving agent |
| US5662934A (en) * | 1993-01-05 | 1997-09-02 | Najarian; Thomas | Compositions and methods for lowering cholesterol while maintaining antioxidant levels |
| EP0904082A4 (en) * | 1996-04-17 | 2001-09-26 | Merck & Co Inc | Combination therapy for reducing the risks associated with cardiovascular disease |
| AU5844196A (en) * | 1996-05-29 | 1998-01-05 | Taisho Pharmaceutical Co., Ltd. | Remedy or preventive for hyperlipemia |
| US6245797B1 (en) * | 1997-10-22 | 2001-06-12 | Merck & Co., Inc. | Combination therapy for reducing the risks associated with cardio-and-cerebrovascular disease |
| UA77660C2 (en) * | 2000-10-03 | 2007-01-15 | Compositions and methods for reducing plasma lipoprotein a level in human |
-
2001
- 2001-12-12 WO PCT/JP2001/010914 patent/WO2002047682A1/en active Application Filing
- 2001-12-12 AU AU2002221131A patent/AU2002221131A1/en not_active Abandoned
- 2001-12-12 CA CA002433285A patent/CA2433285C/en not_active Expired - Fee Related
- 2001-12-12 CN CNB018226396A patent/CN100369605C/en not_active Expired - Fee Related
- 2001-12-14 TW TW090131038A patent/TWI277417B/en not_active IP Right Cessation
-
2003
- 2003-06-12 US US10/461,775 patent/US7012067B2/en not_active Expired - Fee Related
-
2004
- 2004-06-17 HK HK04104416A patent/HK1061518A1/en not_active IP Right Cessation
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1329031C (en) * | 2005-01-24 | 2007-08-01 | 杭州鑫富药业有限公司 | Blood-fat regulating medicinal composition and use thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| HK1061518A1 (en) | 2004-09-24 |
| US7012067B2 (en) | 2006-03-14 |
| CA2433285A1 (en) | 2002-06-20 |
| CA2433285C (en) | 2009-06-23 |
| WO2002047682A1 (en) | 2002-06-20 |
| US20040014712A1 (en) | 2004-01-22 |
| AU2002221131A1 (en) | 2002-06-24 |
| CN100369605C (en) | 2008-02-20 |
| TWI277417B (en) | 2007-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1245157C (en) | Novel fatty analogues for treatment of diabetes | |
| CN1173945C (en) | 5-thia-omega-substituted phenyl-prostaglandin E derivatives, process for producing same and drugs containing same as active ingredient | |
| CN1178656C (en) | Pharmaceutical composition | |
| CN1489462A (en) | Blood lipid ameliopant composition | |
| CN1092418A (en) | New tetrahydrofuran (THF) ketone derivatives | |
| CN1062289A (en) | The treatment heart, blood vessel hypertrophy and outgrowth method | |
| CN1135984C (en) | O/W emulsion composition for eye drops | |
| CN1894251A (en) | Crystalline forms of (6R)-l-erythro-tetrahydrobiopterin dihydrochloride | |
| CN1058399A (en) | New piperidine ether and thioether as cholesteral biosynthesis inhibitor | |
| CN1146414C (en) | Amino acid compositions and use thereof in immunosuppression | |
| CN1159004C (en) | Swallowable tablets with high content of N-acetylcysteine | |
| CN1489461A (en) | Triglyceride depressant composition | |
| CN1216884C (en) | Dibenz [a.g] quinolizinium derivatives and salts thereof | |
| CN101058568A (en) | Novel medicinal salt for cinepazide and preparation method thereof | |
| CN1642911A (en) | Phthalimido derivatives as inhibitors of monoamine oxidase B | |
| CN1025676C (en) | Non-peptidic renin inhibitors | |
| CN1030586A (en) | (8 β)-1-alkyl-6-(replacement) ergoline cycloalkyl amides | |
| CN1033029C (en) | Indenoindole compounds II | |
| CN1148175C (en) | Use of calcium L-threonate in prevention and inhibition of osteoporosis and rickets | |
| CN1422156A (en) | Use of N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds for treating hepatitis virus infections | |
| CN1057647A (en) | New 3,3 '-dithio-two (propionic acid) and ester thereof | |
| CN1763027A (en) | Novel ascorbic acid compounds, methods of synthesis and application use thereof | |
| CN1191241C (en) | Pyridazinyl phenyl hydrazones useful against congestive heart failure | |
| CN1060769C (en) | 1,4-benzoxazine derivatives, pharmaceutical composition containing the same and use thereof | |
| CN1311238C (en) | Hypotensors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1061518 Country of ref document: HK |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1061518 Country of ref document: HK |
|
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080220 Termination date: 20100112 |